Literature DB >> 24256023

Diethylstilboestrol for the treatment of prostate cancer: past, present and future.

Rafal Turo1, Michal Smolski, Rachel Esler, Magda L Kujawa, Stephen J Bromage, Neil Oakley, Adebanji Adeyoju, Stephen C W Brown, Richard Brough, Andrew Sinclair, Gerald N Collins.   

Abstract

The aim of this review was to discuss the most recent data from current trials of diethylstilboestrol (DES) to identify its present role in advanced prostate cancer treatment as new hormonal therapies emerge. The most relevant clinical studies using DES in castration-refractory prostate cancer (CRPC) were identified from the literature. The safety, efficacy, outcomes and mechanisms of action are summarized. In the age of chemotherapy this review highlights the efficacy of oestrogen therapy in CRPC. The optimal point in the therapeutic pathway at which DES should be prescribed remains to be established.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24256023     DOI： 10.3109/21681805.2013.861508

Source DB:  PubMed          Journal:  Scand J Urol        ISSN： 2168-1805            Impact factor:   1.612


  9 in total

Review 1.  Untangling the association between environmental endocrine disruptive chemicals and the etiology of male genitourinary cancers.

Authors:  Tiffani J Houston; Rita Ghosh
Journal:  Biochem Pharmacol       Date:  2019-12-06       Impact factor: 5.858

2.  A generalized theory of separable effects in competing event settings.

Authors:  Mats J Stensrud; Miguel A Hernán; Eric J Tchetgen Tchetgen; James M Robins; Vanessa Didelez; Jessica G Young
Journal:  Lifetime Data Anal       Date:  2021-09-01       Impact factor: 1.429

Review 3.  Immune Relevant and Immune Deficient Mice: Options and Opportunities in Translational Research.

Authors:  Enrico Radaelli; Sara F Santagostino; Rani S Sellers; Cory F Brayton
Journal:  ILAR J       Date:  2018-12-31

4.  Androgen Deprivation Therapy and the Re-emergence of Parenteral Estrogen in Prostate Cancer.

Authors:  Iain Phillips; Syed I A Shah; Trinh Duong; Paul Abel; Ruth E Langley
Journal:  Oncol Hematol Rev       Date:  2014

Review 5.  Contemporary hormone therapy with LHRH agonists for prostate cancer: avoiding osteoporosis and fracture.

Authors:  Hannah C P Wilson; Syed I A Shah; Paul D Abel; Patricia Price; Lesley Honeyfield; Steve Edwards; Richard L Abel
Journal:  Cent European J Urol       Date:  2015-04-20

6.  A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol.

Authors:  Ruth E Langley; Howard G Kynaston; Abdulla A Alhasso; Trinh Duong; Edgar M Paez; Gordana Jovic; Christopher D Scrase; Andrew Robertson; Fay Cafferty; Andrew Welland; Robin Carpenter; Lesley Honeyfield; Richard L Abel; Michael Stone; Mahesh K B Parmar; Paul D Abel
Journal:  Eur Urol       Date:  2015-12-17       Impact factor: 20.096

7.  Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial.

Authors:  Tetsuya Fujimura; Satoru Takahashi; Haruki Kume; Tomohiko Urano; Kenichi Takayama; Yuta Yamada; Motofumi Suzuki; Hiroshi Fukuhara; Tohru Nakagawa; Satoshi Inoue; Yukio Homma
Journal:  BMC Cancer       Date:  2015-11-02       Impact factor: 4.430

8.  Favourable response of serum prostate-specific antigen to conjugated oestrogen in castrate-resistant prostate cancer in Jamaica.

Authors:  Andrew Condappa; Maxine Gossell-Williams; William Aiken
Journal:  Ecancermedicalscience       Date:  2018-04-24

9.  Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi).

Authors:  Herjan J T Coelingh Bennink; Jeroen A van Moorselaar; E David Crawford; Erik P M Roos; Diederik M Somford; Ton A Roeleveld; Tjard D de Haan; Harm H E van Melick; Yacov Reisman; Yvette Zimmerman; Gonnie van Osta; Jan Krijgh; Neal D Shore; Fred Saad; Andrew V Schally; Frans M J Debruyne
Journal:  Eur Urol Open Sci       Date:  2021-05-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.